1. Information about this Guideline – Prevention of Skin Cancer

Office Leitlinienprogramm Onkologie
c/o Deutsche Krebsgesellschaft e. V.
Kuno-Fischer-Straße 80
14057 Berlin

leitlinienprogramm@krebsgesellschaft.de
www.leitlinienprogramm-onkologie.de

 

Leitlinienprogramm-Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Evidence-based Guideline on Prevention of Skin Cancer, Langversion 2.1, 2021, AWMF-Registernummer 032/052OL, https://www.leitlinienprogramm-onkologie.de/leitlinien/hautkrebs-praevention/

September 2021: Version 2.1: The editing mode (reviewed in modified) in Recommendations 4.3., 8.5., 8.9., 8.22., 8.44. was corrected and the listing of changes in Chapter 10 was adjusted accordingly. No substantive changes were made to the recommendations.

 

Medicine is subject to a continuous process of development, so that all information, in particular on diagnostic and therapeutic procedures, can only ever correspond to the state of knowledge at the time of printing of the guideline. The
greatest possible care has been taken withregard to the
recommendations given for therapy and the selection and dosage of medications. Nevertheless, users are urged to consult the manufacturers' package inserts and expert information and, in case of doubt, to consult a specialist
. In the general interest, any discrepancies should be reported to the OL editorial office.

The user himself remains responsible for any diagnostic and therapeutic application, medication and dosage.

In this guideline, registered trademarks (protected trade names) are not specially marked. Therefore, it cannot be concluded from the absence of a corresponding reference that it is a free trade name
.

The work is protected by copyright in all its parts. Any use outside the provisions of copyright law without the written consent of the OL editorial office is prohibited and punishable by law. No part of the work may be reproduced in any form without the written permission of the OL editorial office. This applies in particular to duplications, translations, microfilming and the storage, use and exploitation in electronic systems, intranets and the Internet.

 

This document is the long version of the S3 guideline Prevention of skin cancer. In addition to the long version, there are the following supplementary documents to this guideline:

• Abridged version of the guideline
• Patient guideline
• Guideline report on the guideline development process
• Evidence tables

This guideline and all supplementary documents can be accessed via the following pages.

• Guideline Programme in Oncology(https://www.leitlinienprogramm-onkologie.de/leitlinien/hautkrebs-praevention/)
• AWMF(http://www.leitlinien.net)
• Homepages of the participating professional societies, e.g. Arbeitsgemeinschaft Dermatologische Prävention(http://www.unserehaut.de, http://www.hautkrebs-screening.de)
• Guidelines International Network(http://www.g-i-n.net)

There is a separate S3 guideline on the diagnosis, therapy and aftercare of melanoma within the guideline programme oncology(https://www.leitlinienprogramm-onkologie.de/leitlinien/melanom/), which is also accessible via the websites of the guideline programme oncology and its sponsors.